Get the Stockscreener App
693.50
0.21%
-1.49
After Hours:
692.99
-0.51
-0.07%
Regeneron Pharmaceuticals Inc stock is traded at $693.50, with a volume of 906.90K.
It is down -0.21% in the last 24 hours and up +21.11% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$694.99
Open:
$697.19
24h Volume:
906.90K
Relative Volume:
0.87
Market Cap:
$72.24B
Revenue:
$14.25B
Net Income/Loss:
$4.58B
P/E Ratio:
16.60
EPS:
41.7701
Net Cash Flow:
$3.88B
1W Performance:
+5.47%
1M Performance:
+21.11%
6M Performance:
+21.38%
1Y Performance:
-11.37%
1-Day Range:
$685.95
$699.27
1-Week Range:
$651.38
$713.58
52-Week Range:
$476.49
$800.99
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Why Regeneron Pharmaceuticals Inc. (RGO) stock is listed among top recommendationsPortfolio Risk Summary & Risk Controlled Daily Trade Plans - newser.com
How robust is Regeneron Pharmaceuticals Inc. (RGO) stock financial positionVolume Spike & Fast Moving Stock Watchlists - newser.com
Can Regeneron Pharmaceuticals Inc. stock weather global recessionStop Loss & Growth Focused Investment Plans - newser.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Hold at Scotiabank - MarketBeat
Grandfield & Dodd LLC Boosts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Police & Firemen s Retirement System of New Jersey Has $8.34 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
KBC Group NV Has $19.20 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Banco Bilbao Vizcaya Argentaria S.A. - MarketBeat
How Regeneron Pharmaceuticals Inc. stock responds to policy changes2025 Pullback Review & AI Forecasted Entry/Exit Points - newser.com
How Regeneron Pharmaceuticals Inc. (RGO) stock responds to job market shifts2025 Growth vs Value & Risk Managed Investment Entry Signals - newser.com
A Look at Regeneron Pharmaceuticals’s (REGN) Valuation Following Recent Share Price Gains - simplywall.st
ABN Amro Investment Solutions Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
How strong is Regeneron Pharmaceuticals Inc. stock balance sheetMarket Movers & Daily Volume Surge Trade Alerts - newser.com
Discipline and Rules-Based Execution in REGN Response - news.stocktradersdaily.com
Why Regeneron Pharmaceuticals Inc. stock is considered a top pickBreakout Watch & Safe Swing Trade Setups - newser.com
Regeneron's Saratoga Springs facility - The Post Star
Is Regeneron Pharmaceuticals Inc. stock positioned for digital transformationTrade Analysis Report & Expert-Curated Trade Recommendations - newser.com
What data driven models say about Regeneron Pharmaceuticals Inc.’s future2025 Volume Leaders & AI Powered Trade Plan Recommendations - newser.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Now Covered by Analysts at Scotiabank - MarketBeat
Why millennials buy Regeneron Pharmaceuticals Inc. (RGO) stockMarket Volume Summary & Smart Investment Allocation Insights - newser.com
Biocon Challenges Regeneron Over UK Retinal Pharma Patent - Law360
Vise Technologies Inc. Takes $1.13 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Pet Healthcare Spending Is Soaring. These Stocks Are Positioned to Clean Up - AOL.com
Geode Capital Management LLC Trims Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Plans $2B Facility, Boosting Saratoga Economy - WGY
National Pension Service Boosts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Penserra Capital Management LLC Has $210,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Candriam S.C.A. Sells 72,733 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Bailard Inc. - MarketBeat
CENTRAL TRUST Co Sells 1,069 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
What MACD signals say about Regeneron Pharmaceuticals Inc.July 2025 Gainers & Weekly High Conviction Trade Ideas - newser.com
Regeneron to invest $2 billion into former Quad Graphics facility in Saratoga Springs - The Daily Gazette
Regeneron to expand into Saratoga Co. with new facility - NEWS10 ABC
Regeneron (REGN) Is Up 5.8% After Positive Phase 2 and 3 Data Across Key Clinical Programs - simplywall.st
Regeneron to build $2 billion factory in Saratoga County, create 1,000 jobs - Times Union
Gov. Hochul: Regeneron to invest more than $2B in new Spa City facility - WRGB
Can a trend reversal in Regeneron Pharmaceuticals Inc. lead to recovery2025 Market Sentiment & Free Community Supported Trade Ideas - newser.com
Regeneron Pharmaceuticals Sees Stellar Stock Surge - timothysykes.com
Can Regeneron Pharmaceuticals Inc. stock maintain operating marginsRecession Risk & Technical Pattern Recognition Alerts - newser.com
Can Gilead Stock Outrun Regeneron In The Next Rally? - Forbes
Regeneron (REGN) to Showcase Hematology Advances at ASH 2025 - GuruFocus
CytomX Therapeutics to Present at the Jefferies London Healthcare Conference - GlobeNewswire Inc.
Multiple myeloma drug linvoseltamab to be featured at ASH 2025 meeting - Investing.com Canada
Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs - The Manila Times
Regeneron Pharmaceuticals unveils new blood cancer data at ASH25 - Traders Union
Regeneron Pharmaceuticals Announces New Clinical Data on Lynozyfic™ and Odronextamab to be Presented at ASH 2025 Annual Meeting - Quiver Quantitative
Regeneron (NASDAQ: REGN) highlights oral data for Lynozyfic and odronextamab at ASH - Stock Titan
Is Regeneron Pharmaceuticals Inc. trending in predictive chart modelsPortfolio Value Report & AI Powered Market Trend Analysis - newser.com
Scotiabank Initiates Regeneron Pharmaceuticals at Sector Perform With $650 Price Target - MarketScreener
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.06%
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):